Could a gentler dose of an oral chemo drug help MDS patients avoid transfusions?

NCT ID NCT03502668

Completed Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called ASTX727 in people with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder. The goal was to see if a lower dose given over a longer schedule could improve blood cell counts and reduce the need for transfusions. The trial enrolled 160 adults and looked at safety and effectiveness in two phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASTX727 (oral decitabine and cedazuridine)
What this could lead to: If successful, this could offer a more convenient oral treatment option for people with lower-risk MDS, potentially improving blood cell counts and reducing transfusion needs.
What could go wrong: This is an early-phase trial with small groups, so results may not confirm benefit. The drug can cause side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Az St-Jan Brugge-Oostende A.V.

Bruges, Belgium
BRCR Medical Center Inc.

Plantation, Florida, 33324, United States
Hospital General Universitario Gregorio Marañón

Madrid, Spain
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia

Valencia, 46026, Spain
Hospital Universitario Vall d Hebron

Barcelona, Spain
Indiana University Health Hospital - Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol

Barcelona, Spain
London Regional Cancer Center

London, Ontario, N6A 5W9, Canada
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Moffitt Cancer Center Site#507

Tampa, Florida, 33612, United States
Oregon Health and Science University Knight Cancer Institute

Portland, Oregon, 97239, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Texas Oncology - Tyler

Tyler, Texas, 75702, United States
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)

Bethesda, Maryland, 20817, United States
The University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
The University of Chicago

Chicago, Illinois, 60637, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Universita degli Studi di Firenze

Florence, Italy
Universitaetsklinikum Freiburg Site#703

Freiburg im Breisgau, 79106, Germany
University of Alberta Hospital - Hematology Research

Edmonton, T6G 2B7, Canada
University of Colorado, Anschutz Cancer Pavilion

Aurora, Colorado, 80045, United States
University of Kansas Clinical Research Center

Westwood, Kansas, 66205, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Universitätsklinikum Halle

Halle, 06120, Germany
Vanderbilt University Medical Center - Hematology-Oncology

Nashville, Tennessee, 37232, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States
ZNA - Campus Middelheim

Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.